Adial Pharmaceuticals Inc expected to post a loss of $1.03 a share - Earnings Preview

Adial Pharmaceuticals

07/08/2026 21:38

Adial Pharmaceuticals Inc ADIL.OQ ADIL.O is expected to  show no change in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Adial Pharmaceuticals Inc is for a loss of $1.03 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Adial Pharmaceuticals Inc is $8.00, about 66.7% above its last closing price of $4.80
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-2.73
-2.73
-1.48
Beat
45.8
Dec. 31 2026
-2.01
-2.15
-3.07
Missed
-43
Sep. 30 2025
-3.91
-3.50
-2.00
Beat
42.9​
Jun. 30 2025
-5.50
-6.25
-4.50
Beat
28
​​Mar. 31 2025
-11.26
-12.37
-8.50
Beat
31.3
Dec. 31 2024
-9.37
-9.50
-8.75
Beat
7.9​
Sep. 30 2024
-11.59
-11.00
-9.50
Beat
13.6
Jun. 30 2024
-13.35
-13.37
-14.75
Missed
-10.3
This summary was machine generated August 7 at 20:38 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)